Vi har mer “deal-making” krutt i f.eks Eva Lotta Allan. Generelt sett ser det ut til å være et meget kompetent og erfarent styre.
"Eva-Lotta Allan is an experienced biotechnology deal-maker with over 25 years of business development experience from the biotechnology and life science industry in both private and public companies. She has significant operational and investor relations expertise. Until the end of April 2018, Ms. Allan was Chief Business Officer at Immunocore, an immune-oncology company specializing in the development of soluble T-cell receptor based drugs. Immunocore secured Europe’s largest private life sciences financing in July 2015. Ms. Allan was previously at Ablynx NV, where she served as Chief Business Officer for close to seven years and brought in multiple strategic partnerships. She is the Non-Executive Chairman of C4X Discovery and serves as Non-Executive Director of Crescendo Biologics’ Board and of Aleta Biotherapeutics’ Board. Prior to Ablynx, Ms. Allan served as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals, where she was also a Director of the Board of Vertex Europe. She received her degree in microbiology from the University of Stockholm. Ms. Allan is a Swedish citizen, and resides in the United Kingdom."
Dr. Wheeler has had a long and distinguished international career in drug development spanning 20 years. Most recently she was Chief Medical Officer at Acetylon Pharmaceutical and prior to that held progressively senior clinical and business development roles at AstraZeneca, and Roche, where Dr. Wheeler worked on a number of Phase I-III global oncology programs and had significant interaction with the regulatory bodies including the US Food and Drug Administration (FDA). Additionally, she was an established global consultant and Clinical Associate Professor of Medicine at Harvard Medical School, which she joined in 1981. Dr. Wheeler is Board Certified in Internal Medicine with sub-specialties in Haematology and Medical Oncology
Robert Burns is an advisor to companies developing immune based therapies in cancer and autoimmune indications. He has been involved for more than 30 years in building biotechnology companies focused on immuno-oncology. Dr. Burns is currently Chairman of Affibody AB in Sweden, a company developing novel therapies in autoimmune and inflammation indications. Dr. Burns was a member of the board of directors of Oncos Therapeutics OY prior to the Company’s acquisition of Targovax Oy. He was previously chairman of the board of directors of Haemostatix Limited before it was acquired by Ergomed plc. He was also previously CEO at 4-Antibody AG, Affitech A/S (NASDAQ/OMX) and Celldex Therapeutics Inc (NASDAQ), each an immuno-oncology vaccine and antibody discovery company. Prior to Celldex Therapeutics, Dr. Burns was Director of Technology Licensing at the Ludwig Institute for Cancer Research, an international independently financed not-for-profit research group focused on cancer vaccines and antibody based cancer immunotherapies. He holds a PhD in Chemistry and is a UK citizen, residing in Oxford, United Kingdom.
).
